中国P站

Airway Epithelium; Mucus; Inflammation; Microbiome; Asthma; COPD; Cystic Fibrosis; Air Pollution; Remodeling; Immune Response

Introduction

Airway epithelial cells are central to the immune response against respiratory pathogens, but their dysfunction can trigger inflammatory lung diseases[1].

Mucus hypersecretion and impaired mucociliary clearance are key features of chronic airway diseases, making mucin production a prime therapeutic target[2].

Exposure to air pollution causes oxidative stress and inflammation in the airway mucosa, suggesting antioxidant therapies could be beneficial[3].

Viral infections can compromise the airway epithelium, increasing susceptibility to secondary bacterial infections, highlighting the need to understand viral-bacterial interactions[4].

The airway microbiome influences host immunity and susceptibility to respiratory diseases, with dysbiosis potentially leading to chronic inflammation[5].

Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) dysfunction disrupts airway surface liquid composition and mucociliary clearance, but CFTR modulators can improve airway health[6].

Eosinophilic inflammation is a hallmark of airway diseases like asthma, making eosinophil targeting a viable therapeutic strategy[7].

Neutrophilic inflammation is prevalent in Chronic Obstructive Pulmonary Disease (COPD) and other chronic airway diseases, making understanding neutrophil recruitment and activation vital[8].

Airway remodeling, including fibrosis and smooth muscle hyperplasia, contributes to irreversible airflow obstruction, so targeting remodeling processes is crucial[9].

The airway mucosa is a complex environment with diverse immune cells and structural components; systems biology approaches are essential for a comprehensive understanding[10].

Description

The airway epithelium acts as a critical barrier against inhaled pathogens and environmental insults[1]. When this barrier is disrupted, as seen in conditions like asthma, it can lead to increased inflammation and susceptibility to infection[1]. Understanding the mechanisms that maintain epithelial integrity is therefore essential for developing effective therapies for respiratory diseases[1].

Mucus hypersecretion and impaired mucociliary clearance are common features of chronic airway diseases such as chronic bronchitis and Cystic Fibrosis (CF)[2]. This creates a vicious cycle of inflammation and infection that further damages the airways[2]. Targeting mucin production, a key component of mucus, is a promising strategy for restoring normal airway function[2].

Exposure to air pollution triggers oxidative stress and inflammation in the airways[3]. This can exacerbate existing respiratory conditions and increase the risk of developing new ones[3]. Antioxidant therapies may offer a way to protect the airways from the harmful effects of air pollution[3]. Viral infections, such as influenza and Respiratory Syncytial Virus (RSV), can also disrupt the airway epithelium, making it more vulnerable to secondary bacterial infections[4]. This highlights the importance of understanding how viruses and bacteria interact in the airways.

The airway microbiome plays a vital role in shaping host immunity and influencing susceptibility to respiratory diseases[5]. A healthy microbiome helps to defend against pathogens and maintain immune homeostasis, while dysbiosis can contribute to chronic inflammation[5]. Factors such as antibiotic use, air pollution, and viral infections can disrupt the balance of the airway microbiome.

In Cystic Fibrosis (CF), a defective CFTR protein leads to altered airway surface liquid composition and impaired mucociliary clearance[6]. This results in thick, sticky mucus that clogs the airways and promotes chronic infection[6]. CFTR modulators are a new class of drugs that can improve CFTR function and restore normal airway health[6]. Eosinophilic and neutrophilic inflammation are common features of many airway diseases[7, 8]. Targeting these inflammatory cells is a therapeutic strategy for asthma and COPD, respectively[7, 8]. Finally, airway remodeling contributes to irreversible airflow obstruction[9]. Therefore, therapies targeting remodeling processes are essential for slowing disease progression[9]. The airway mucosa is a complex environment that requires systems biology approaches[10].

Conclusion

The airway epithelium plays a vital role in defending against respiratory pathogens, but its dysfunction contributes to inflammatory lung diseases. Mucus hypersecretion and impaired mucociliary clearance are hallmarks of chronic airway diseases, making mucin production a therapeutic target. Air pollution exposure leads to oxidative stress and inflammation in the airway mucosa, suggesting antioxidant therapies could be beneficial. Viral infections can disrupt the airway epithelium, promoting secondary bacterial infections, emphasizing the need to understand viral-bacterial interactions. The airway microbiome influences host immunity and susceptibility to respiratory diseases, with dysbiosis contributing to chronic inflammation. Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) dysfunction alters airway surface liquid composition and mucociliary clearance, but CFTR modulators can improve airway health. Eosinophilic and neutrophilic inflammation are characteristic of certain airway diseases, such as asthma and Chronic Obstructive Pulmonary Disease (COPD), respectively. Airway remodeling, including fibrosis and smooth muscle hyperplasia, contributes to irreversible airflow obstruction, making targeting remodeling processes crucial. The airway mucosa is a complex environment requiring systems biology approaches for comprehensive understanding.

References

1. Abhishek AK, Bhushan B, Asif S (2023) .Am J Respir Cell Mol Biol 68:17-30.

   , ,

2. Stuart K, Gemma S, Katie M (2018) .Eur Respir Rev 28:180071.

   , ,

3. Jocelyne C, Isabelle G, Eric G (2019) .Curr Opin Pulm Med 25:44-51.

   , ,

4. Ville TP, Sejal EH, Neil WB (2021) .Nat Commun 12:3137.

   , ,

5. Robert PD, Judith RE, Christopher MF (2017) .Ann Am Thorac Soc 14:S48-S53.

   , ,

6. Steven MR, John PC, Christopher G (2017) .Cold Spring Harb Perspect Med 7:a022965.

   , ,

7. Jun S, Kiyoyuki S, Masakazu A (2020) .Allergol Int 69:131-139.

   , ,

8. Alvar A, Xavier F, Carmen F (2020) .Thorax 75:700-708.

   , ,

9. Reynold KL, John PW, Albert vV (2021) .Eur Respir J 58:2003616.

   , ,

10. Stephen TH, Sally W, David HB (2015) .Nat Rev Dis Primers 1:15025.

    , ,